These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 16956486

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL, Tapson VF, Gomberg-Maitland M, Poms A, Barst RJ, McLaughlin VV.
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Treprostinil sodium Pharmacia.
    Chattaraj SC.
    Curr Opin Investig Drugs; 2002 Apr; 3(4):582-6. PubMed ID: 12090728
    [Abstract] [Full Text] [Related]

  • 6. Treprostinil for the treatment of pulmonary arterial hypertension.
    Torres F, Rubin LJ.
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia.
    Brass EP, Anthony R, Dormandy J, Hiatt WR, Jiao J, Nakanishi A, McNamara T, Nehler M, Circulase investigators.
    J Vasc Surg; 2006 Apr; 43(4):752-9. PubMed ID: 16616232
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.
    Jones A, Wang-Smith L, Pham T, Laliberte K.
    J Cardiovasc Pharmacol; 2014 Mar; 63(3):227-32. PubMed ID: 24603117
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.
    Rubenfire M, McLaughlin VV, Allen RP, Elliott G, Park MH, Wade M, Schilz R.
    Chest; 2007 Sep; 132(3):757-63. PubMed ID: 17400684
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
    Minai OA, Parambil J, Dweik RA, Davila GH, Peterson L, Rollins KD, Chen H.
    Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
    [Abstract] [Full Text] [Related]

  • 17. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
    Gessler T, Seeger W, Schmehl T.
    Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.